Adial Pharmaceuticals, Inc. (ADIL)

NASDAQ: ADIL · Real-Time Price · USD

3.920

-0.300 (-7.11%)

Oct 23, 2026, 4:00 PM EDT - Market closed

Adial Pharmaceuticals Earnings Call Transcripts

Fiscal Year 2026

M&A announcement
The acquisition brings a novel, colon-targeted therapy for ulcerative colitis and up to $64M in financing, with Azora equity holders gaining majority ownership. The combined company will focus on advancing AT177 through early clinical milestones.

Read full transcript →

Press release